Former SVP, Corporate Strategy and General Counsel · Atara Biotherapeutics, Inc. (ATRA)

Mina Kim

A named executive officer of Atara Biotherapeutics in every fiscal year CompBrief holds from FY2018 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$2,328,833

Salary $364,494Stock awards $1,034,714

FY2018: $3,384,425

6th of 6 named executive officers at Atara Biotherapeutics by FY2019 total.

6 named officers on file for Atara Biotherapeutics, FY2019

Mina Kim’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • ATRA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Atara Biotherapeutics’s whole pay program stands against its peers

  • Atara Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ATRA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2020 (DEF 14A).

Free

Get Mina Kim’s full pay file as a PDF — free

More than this page: up to 10 years of Mina’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mina Kim compensation by year

Atara Biotherapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Atara Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019
Salary$266,827$364,494
Bonus$101,730$0
Stock awards$1,530,000$1,034,714
Option awards$1,485,365$909,080
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$504$20,546
Total$3,384,425$2,328,833

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Atara Biotherapeutics, Inc. DEF 14A filed April 22, 2020, accession 0001564590-20-017935, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Atara Biotherapeutics, Inc. filed document, accession 0001564590-20-017935. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2020.

$3.4M
$2.3M
FY18
FY19
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU31,875$524,981—
RSU17,063$281,028—
RSU10,000$164,700—
Option40,833—$36.00
Option27,016—$38.47

Per the Outstanding Equity Awards at Fiscal Year-End table in Atara Biotherapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Atara Biotherapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Isaac CiechanoverFormer President & Chief Executive Officer$8,014,771
Pascal TouchonPresident & Chief Executive Officer$6,637,307
Dietmar BergerFormer Global Head of Research & Development$3,245,062
Joseph NewellEVP, Chief Operations Officer$2,719,167
Utpal KoppikarChief Financial Officer$2,540,170
Mina Kim · this pageFormer SVP, Corporate Strategy and General Counsel$2,328,833

The full Atara Biotherapeutics compensation record

free company brief

This page is one person within Atara Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Atara Biotherapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Atara Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mina Kim's compensation dossier · One-time report. No refunds.